Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD)

Limitations in efficacy and high relapse rates of currently available smoking cessation agents reveal the need for more efficacious pharmacotherapies. One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dwoskin, Linda P., Joyce, B. Matthew, Zheng, Guangrong, Neugebauer, Nichole M., Manda, Vamshi K., Lockman, Paul, Papke, Roger L., Bardo, Michael T., Crooks, Peter A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2007
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2104778/
https://ncbi.nlm.nih.gov/pubmed/17727820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2007.07.021
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares